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Background and Objective: People living with HIV who are receiving antiretroviral 
therapy need to be monitored to evaluate treatment failure.  Gold standard plasma 
viral load is logistically difficult in many resource-limited settings; dried blood spot 
viral load testing may be a more accessible alternative.   A Markov state-transition 
model was created in order to better evaluate the clinical consequences of this 
alternative.  Outcomes were compared to those of plasma viral load, CD4 
immunologic criteria, and clinical criteria for treatment failure. 
 
Methods: A Markov state-transition model was created with two cohorts of 10,000 
sub-Saharan African adults, one ART naïve cohort and one ART experienced cohort.  
Outcomes of each cohort were simulated over 5 years of follow-up.  Outcomes of 
interest were the number of patients who died or were virologically failing after five 
years, events of interest were cumulative misclassifications over five years. 
 
Results: Dried blood spot viral load testing was 91% as effective as plasma viral 
load at averting deaths in the ART naïve cohort and 85% as effective in the ART 
experienced cohort, compared with clinical symptoms monitoring alone.  There 
were more misclassifications with dried blood spot viral load than with plasma viral 
load.  Both dried blood spot and plasma viral load testing lead to fewer deaths and 
misclassifications than either clinical criteria for treatment failure alone or 
immunologic criteria.  Estimated programmatic costs for plasma viral load and dried 
blood spot viral load testing were comparable. 
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Conclusions:  Dried blood spot viral load is a good alternative to plasma viral load 
(when the latter is unavailable), with comparable clinical consequences and costs.  
Viral load should continue to be the treatment monitoring mode of choice, as clinical 
and immunologic criteria are inadequate for timely and correct determination of 
treatment failure. 
 









I would like to first and foremost thank my wonderful advisers, David Dowdy 
and Katie Sutcliffe, who tirelessly worked with my “abbreviated” time constraints 
and incessant requests for feedback.  I hope I didn’t drive you both crazy.  I would 
like to thank Homayoon Farzadegan and Frank Curriero, who helped me develop my 
teaching skills this year and earn a couple bucks doing so.  I need to again thank my 
college adviser, Kirk Miller, who continues to listen to and encourage me to do 
better, even though he technically has no ongoing responsibility for my education or 
career.  I would like to thank my friends from Hopkins, especially Saul Feinstein, 
Amrita Rao, Molly Deutsch-Feldman, Diana Higuera, Cassie Ott, Ruth Geller, Ruthie 
Burrows, and my friends from elsewhere, especially Ryan Akman, Eric Tien, David 
Kaufman, Ben Tipper, Jack Flowers, Ezra Park, Rob Wilkie, Eric Li, Matt Klimuszka, 
and Griffin Rhodes.  I should also probably thank my family, who have had to deal 
with me for 21 24 years now.  I would most of all like to thank my girlfriend, Helen 
Ryan, who has now endured two theses from me and still decided of her own free 
will to stick around. 
 
“May science give us the courage to do what we must.” 

















 Primary Outcomes………………………………………………………………………………...13 
 Secondary Outcomes………………………………………………………………………….....13 
 Cost………………………………………………………………………………………………………..14 















 Supplement 1. Overview of the Current State of Treatment Monitoring……26 
Supplement 2. Parameter Revisions………………………………………………………..29 
 Inclusion Criteria………………………………………………………………………..30 
 Literature Review Search Process…………………………………………...…30 







LIST OF TABLES 
Table 1. Base case Markov model epidemiological parameters ….….………………...….47 
Table 2. Base case screening accuracy parameters …………………..…………………………48 
Table 3. Base case cost parameters ……………………………………………………………………49 
Table 4a. Number of deaths among 10,000 ART naive patients after 5 years of 
follow-up, varying sensitivity and specificity of the DBS viral load assay……………....50 
Table 4b. Number of deaths among 10,000 ART experienced patients after 5 years 
of follow-up, varying sensitivity and specificity of the DBS viral load assay…………..50 
Table 4c. Number of downclassifications among 10,000 ART naive patients after 5 
years of follow-up, varying sensitivity and specificity of the DBS viral load assay….51 
Table 4d. Number of downclassifications among 10,000 ART experienced patients 
after 5 years of follow-up, varying sensitivity and specificity of the DBS viral load 
assay………………………………………………………………………………………………………………….51 
Table 4e. Number of upclassifications among 10,000 ART naive patients after 5 
years of follow-up, varying sensitivity and specificity of the DBS viral load assay….52 
Table 4f. Number of upclassifications among 10,000 ART experienced patients after 
5 years of follow-up, varying sensitivity and specificity of the DBS viral load assay 
………………………………………………………………………………………………………………………….52 
Table 4g. Overall costs for 10,000 ART naive patients after 5 years of follow-up, 
varying sensitivity and specificity of the DBS viral load assay………………………………53 
Table 4h. Overall costs for 10,000 ART experienced patients after 5 years of follow-




LIST OF FIGURES 
Figure 1. Set of feasible Markov states and transitions as a result of virologic 
monitoring and failure………………………………………………………………………………………..54 
Figure 2. Set of feasible Markov state combinations of virologic monitoring and 
disease progression……………………………………………………………………………………………55 
Figure 3a. Deaths among 10,000 ART naïve and experienced patients after 5 years 
of follow-up, by treatment failure test…………………………………………………………………56 
Figure 3b. Incremental deaths (compared with CSM) among 10,000 ART naïve and 
experienced patients after 5 years of follow-up, by treatment failure test……………..57 
Figure 3c. Deaths among 10,000 ART naïve and experienced patients after 5 years 
of follow-up, by commercial DBS viral load assay………………………………………………...58 
Figure 4a. Up- and downclassification among 10,000 ART naïve and experienced 
patients after 5 years of follow-up, by treatment failure test………………………………...59 
Figure 4b. Number virologically failing (viral load above 1,000 copies/mL) among 
10,000 ART naïve and experienced patients after 5 years of follow-up, by treatment 
failure test………………………………………………………………………………………………………….60 
Figure 4c. Up- and downclassification among 10,000 ART naïve and experienced 
patients after 5 years of follow-up, by commercial DBS viral load assay………………..61 
Figure 5a. Cost and incremental cost (compared with CSM) among 10,000 ART 
naïve and experienced patients over 5 years of follow-up, by treatment failure test 
………………………………………………………………………………………………………………………….62 
Figure 5b. Incremental cost per death averted (compared with CSM) among 10,000 
ART naïve and experienced patients over 5 years of follow-up, by treatment failure 
test…………………………………………………………………………………………………………………….63 
Figure 6a. Deaths among 10,000 ART naïve and experienced patients after 5 years 
of follow-up, varying sensitivity of the DBS assay………………………………………………...64 
Figure 6b. Deaths among 10,000 ART naïve and experienced patients after 5 years 
of follow-up, varying specificity of the DBS assay…………………………………………………65 
Figure 6c. Up- and downclassification among 10,000 ART naïve and experienced 
patients after 5 years of follow-up, varying sensitivity of the DBS assay………………..66 
ix 
 
Figure 6d. Up- and downclassification among 10,000 ART naïve and experienced 
patients after 5 years of follow-up, varying specificity of the DBS assay………………..67 
Figure 7a. Deaths among 10,000 ART naïve and experienced patients after 5 years 
of follow-up, varying switch rate per follow-up period due to intolerance for DBS 
………………………………………………………………………………………………………………………….68 
Figure 7b. Deaths among 10,000 ART naïve and experienced patients after 5 years 





LIST OF SUPPLEMENT TABLES AND FIGURES 
Supplement Table T1. Base case Markov model epidemiological parameters…..…70 
Supplement Table T2. Base case screening accuracy parameters……………………….72 
Supplement Table T3. Base case Markov model cost parameters……………………….73 
Supplement Literature Review S1. Treatment Failure Test Mortality Parameters 
………………………………………………………………………………………………………………………….74 





Global prevalence of HIV infection is estimated by the United Nations to be 36.7 
million people, with most of the burden in low-and-middle-income countries 
(LMIC)  (UNAIDS 2016). Highly-active anti-retroviral therapy (ART) coverage is 
estimated to be 46% (UNAIDS 2016).  While gains over the last few years have been 
great (including a more than doubling in coverage in South and East Africa), there is a 
long way to go to reach the UNAIDS target of  “90-90-90” for the year 2020, “whereby 
90% of people living with HIV know their HIV status, 90% of people who know their 
HIV-positive status are accessing treatment and 90% of people on treatment have 
suppressed viral loads”  (UNAIDS 2014). 
Individuals receiving ART need to be monitored to predict treatment progress and 
evaluate treatment failure (Mellors et al. 1997).  Treatment failure is determined through 
one or more of three criteria: virologic criteria (through viral load, the number of RNA 
copies of the virus per milliliter of blood), immunologic criteria (through CD4 count, the 
number of CD4 cells per milliliter of blood; referred to here as “CD4”), or clinical criteria 
(through clinical progression, marked by an HIV-related illness or other clinical sequela; 
referred to here as “CSM”) (Mellors et al. 1997; World Health Organization 2016).  An 
individual with successful treatment will have low or undetectable viral load, minimal 
decrease in successive CD4 counts, and no clinical progression (World Health 
Organization 2016).  An individual failing treatment should change to different available 
line of ART in an attempt to improve viral suppression (Mellors et al. 1997; Mee et al. 
2008; Rutherford et al. 2014; World Health Organization 2016). 
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CD4 is the traditional prognostic marker of HIV (Mellors et al. 1997), though 
viral load is the widely accepted and WHO-officially recommended treatment failure 
monitoring method when available (World Health Organization 2016).  At worst, it is 
noninferior to CD4 in reducing mortality through treatment monitoring (Boyer et al. 
2013; Jourdain et al. 2013; Mermin et al. 2011; Laurent et al. 2011; A. N. Phillips et al. 
2008; Tucker et al. 2014), but it is widely viewed as superior (Chaiwarith et al. 2007; 
Mee et al. 2008; Ferreyra et al. 2012; Rawizza et al. 2011; Rutherford et al. 2014; Shen et 
al. 2016; Ingole et al. 2013; Hamers et al. 2012).  Viral load monitoring increases life 
expectancy (Hamers et al. 2012), reduces risk of misdiagnosis of treatment failure 
(Hamers et al. 2012), reduces risk of drug resistance (Hamers et al. 2012; World Health 
Organization 2016), and may be cost-saving (Hamers et al. 2012).  Clinical symptoms 
should also be monitored (CSM) as standard practice, though it is not an effective method 
of determining treatment failure (Rutherford et al. 2014; World Health Organization 
2016). 
Unfortunately, there have been persistent challenges in implementing viral load 
monitoring in LMIC (Madec et al. 2013; UNAIDS 2016).  In addition to the low uptake 
of treatment itself (UNAIDS 2016), treatment monitoring has an even lower uptake 
(Neogi et al. 2011).  Currently, plasma viral load (PVL) is the gold standard viral load 
monitoring method of choice (Fajardo et al. 2014).  PVL is widely available in the 
developed world, but is logistically difficult in high-burden LMIC due to the need for 
phlebotomy to obtain, freezers to preserve, and vehicles to transport plasma samples 
(Neogi et al. 2011).  In addition to complicated sample handling, PVL necessitates a 
professional laboratory with specialized equipment and trained staff (Neogi et al. 
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2011).  An emerging alternative to PVL is dried blood spot (DBS) viral load.  DBS 
samples eschew some of the logistical difficulty presented by plasma samples, as they do 
not need to be professionally obtained, carefully preserved, or tenuously transported 
(Neogi et al. 2011; Rutstein et al. 2015).  Laboratory facilities are still required for DBS 
analysis, but DBS samples can be transported cheaply through municipal mail services 
(Lofgren et al. 2009). 
The logistical advantages of DBS come at the cost of decreased accuracy (Fajardo 
et al. 2014).  Lower sensitivity may result in fewer virally unsuppressed people being 
successfully identified and moved from first-line ART to second-line ART, whereas 
lower specificity may result in more virally suppressed people being misidentified as 
virally unsuppressed and unnecessarily moved from first-line ART to second-line 
ART.  At a population level, it is certain there will be different costs and outcomes 
associated with different treatment monitoring types.  A Markov state-transition model 
was created here in order to better evaluate the clinical consequences of using DBS for 
viral load testing and determine the accuracy threshold needed for DBS to be a desirable 






A Markov state-transition model was created with two cohorts of 10,000 
sub-Saharan African adults, one ART naïve cohort (initiating first-line ART) and one 
ART experienced cohort (virologically suppressed and on first-line ART).  The 
outcomes of each cohort were simulated over 5 years of follow-up.  The primary 
aims of this analysis were threefold: 
1. To compare the clinical consequences of DBS to PVL in order to evaluate 
acceptability of DBS where PVL is not available. 
2. To compare the clinical consequences of DBS to CSM and CD4 in order to 
quantify the advantages of viral load testing for evaluating treatment failure. 
3. To measure the effects of varying assumptions about the accuracy of DBS 
viral load testing (relative to PVL) on clinical consequences. 
 
True treatment failure was defined as a true plasma viral load in excess of 
1,000 copies/mL (also referred to as virologic failure), as consistent with the 
current WHO criteria for treatment failure (World Health Organization 
2016).  Measured treatment failure for viral load tests (DBS or PVL) was defined as 
two consecutive viral load measurements, 3-6 months apart, in excess of 1,000 
copies/mL, consistent with the current WHO criteria for viral load testing (World 
Health Organization 2016).  Measured treatment failure for CSM was defined as a 
positive clinical diagnosis of an HIV-associated illness.  Measured treatment failure 
for CD4 count was defined as a decline to baseline or persistent CD4 count below 
100 cells/mL (World Health Organization 2016).  Measured treatment failure is 
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distinguished from true treatment failure, as the tests (measurements) can 
misclassify. 
The main outcome of interest was the number of patients who died after 5 
years of follow-up.  Events of interest include the number of patients who were 
upclassified (unnecessarily switched to second-line ART, despite treatment success, 
due to a false positive test) and the number of patients who were downclassified 
(unnecessarily kept on first-line ART, despite treatment failure, due to a false 
negative test).   Also of interest was the number of patients who were virologically 
failing at the end of follow-up, including both those failing on first-line ART and 
those who experienced true treatment failure while on second-line ART.  Total 
systemic costs for each cohort after 5 years were also estimated as a crude measure 
of comparing cost effectiveness among the treatment monitoring methods. 
 
Model Structure 
The model followed a simplified Markov state-transition model of HIV 
treatment, monitoring, and disease progression (Figure 1).  A Markov model 
assumes that individuals are divided into states of some process, with a discrete 
probability of moving to a different state over the time of observation.  Future states 
are dependent only on the current state, so individuals on second-line therapy 
cannot return to first-line therapy, and individuals who die cannot move to any 
other state. 
The two parallel model components, treatment monitoring and disease 
progression, together comprise the 25 total possible states (24 living states and the 
death state) at each time interval (Figure 2).  The treatment monitoring component 
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follows the outcomes of the tests for treatment failure (DBS, PVL, CSM, or CD4), 
whereas the disease progression follows the true immunologic state of the 
individual (true CD4 count).  At entry to the cohort, all patients are considered to be 
alive, virally suppressed, and on first-line ART (or starting first-line ART if they are 
ART naïve).  At exit from the cohort, patients are defined by their regimen (first or 
second-line), viral load (suppressed or unsuppressed), and vital status (alive or 
dead). 
For simplicity, a minimum number of assumptions were made, and for 
transparency, assumptions and parameters were chosen for source availability to 
(and ease of modification by) readers.  This flexibility lends itself to easier 
individualized analysis for decision-making, as well as sensitivity analysis.  This 
model is expected to have less fidelity as a trade-off for simplicity, though this loss is 
hopefully mitigated by its flexibility. 
Virologic testing and treatment monitoring occurred at six and twelve 
months after entry into the cohort, as well as every twelve months thereafter, for 
ART naïve patients (up to seven measurements).  Virologic testing and treatment 
monitoring occurred every twelve months after entry into the cohort for ART 
experienced patients (up to six measurements).  The treatment and virologic 
monitoring model component used time steps of six months over the course of the 
full five-year projection.  In each state, the model first assessed the probability of 
virologic failure, then applied sensitivity and specificity assumptions for the defined 
treatment monitoring strategy and assumed that all patients would receive 
treatment based on the test results.  For an individual on first-line ART, a positive 
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test means switching to second-line ART; a negative test means remaining on first-
line ART.  Individuals who test positive would require a second test in the same time 
interval before switching to second-line ART.  Tests performed during one time 
interval were assumed to result in any changes necessary by the next time interval 
(with a 100% treatment line switch rate). 
 
Updates 
The model presented in this manuscript was originally constructed by Mark 
Moses and David Dowdy, and first presented in Costs and Consequences of Viral 
Load Monitoring with Dried Blood Spots versus Plasma in Resource-Limited 
Settings, a report for the World Health Organization HIV Treatment Guidelines 
Development Committee.  This report was published May 2015.  This model has 
been adapted and modified substantially for 2016, following an updated review of 
the literature (see Supplement for details). 
 
State-transition Parameters 
Initial distribution of CD4 states in the cohort of ART naïve patients was 
ascertained from a cohort study conducted in Kenya, Uganda, and Zambia, chosen 
for their representativeness of high-burden, resource-limited settings (Institute for 
Health Metrics and Evaluation 2015).  Raw data is available on their web repository 
(http://ghdx.healthdata.org/ihme_data), and is merged from the Access, 
Bottlenecks, Costs, and Equity Project 2012 in Kenya, Uganda, and Zambia.  Data 
from Ghana is not included due to the lack of chart extraction data.  The study by 
Maduna in South Africa was considered, but discarded because it included a mixture 
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of patients on and not on ART at baseline, and a stratified distribution was not 
reported (Maduna et al. 2015).  Initial distribution of CD4 states of the cohort of ART 
experienced patients was calibrated at entry to the CD4 count distribution of ART 
naïve patients who were on first-line ART and virologically suppressed after 5 years. 
Disease progression was modeled by differential risk of transition and 
mortality at different CD4+ T-cell count states (> 350, 350-200, 199-100, and < 100 
cells/mL) and contingent on viral suppression (assumed from treatment success; 
suppressed individuals gain CD4, unsuppressed individuals lose CD4).  Individual 
state transition and mortality risk was probabilistically dependent on treatment in 
the current state.  Disease progression was assumed to occur at the same rate in 
individuals with virologic failure as those who are ART naïve (Mellors et al. 1997; 
Maduna et al. 2015), though mortality was assumed to be influenced by ART, even 
among unsuppressed individuals (Maduna et al. 2015).  A similar, more recent study 
in sub-Saharan Africa by Cori et al. was considered as an alternative, though the CD4 
grouping categories used in that analysis did not line up with this model (Cori et al. 
2015).   CD4 transition probabilities among suppressed patients were taken from 
Gabillard et al. and follow the WHO immunological staging system with an 
additional granular category at the lower end of the spectrum (below simply “AIDS” 
or <200 cells/mL) (Gabillard et al. 2013).  
Viral suppression probabilities were taken from a trio of studies.  First line, 
suppressed to unsuppressed, was taken from Fox et al. (Fox et al. 2012); second-
line, suppressed to unsuppressed, was taken from Ajose et al. (Ajose et al. 2012); 
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and first line, suppressed to unsuppressed in the first 6 months was taken from 
Barth et al. (Barth et al. 2010). 
Transition probabilities which did not line up with the 6-month-per-state 
timeline used in this model were transformed assuming an exponential CD4 
transition distribution to fit the timeline of this model (Drabick et al. 1992). 
Mortality probabilities were taken from Maduna et al. using the cohort on 
ART (Maduna et al. 2015).  Gabillard et al. was considered as an alternative 
(Gabillard et al. 2013), though Maduna et al. was more recent and used a solely 
African cohort (versus an African and Asian cohort), which was more appropriate 
for our target analytic population. 
The initial model did not assume treatment side effects, toxicity, or 
intolerance to be a failure of first-line ART, nor did it assume loss of samples or loss 
of patients to follow-up.  Third-line and fourth-line ART were also assumed to be 
unavailable.  If patients switched to second-line therapy, their costs of care and 
disease progression continued to be projected, but we therefore assumed their 
treatment monitoring would end (given that there is no other treatment line to be 
switched to and they cannot switch back to first-line ART).  The model also did not 
account for disability or quality of life adjustments, opportunistic infections, or HIV 
transmission.  Initial distribution, mortality, virologic failure, and state-transition 
probabilities are reported in Table 1. 
 
Comparisons 
DBS, PVL, CSM, and CD4 count were compared in the baseline 
analysis.  Baseline accuracy measurements for DBS and PVL were informed based 
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on a review of the literature.  For the purposes of comparison in this analysis, PVL is 
assumed to be the gold standard test with a perfect 100% sensitivity and 100% 
specificity.  Accuracies of treatment monitoring methods are reported in Table 2. 
Six commercial DBS assays were also compared, including the Abbott 
Molecular: Abbott RealTime HIV-1 assays with m2000rt platform (“Abbott”), 
Biocentric: Generic HIV Charge Virale (“Biocentric”), bioMérieux: NucliSENS 
EasyQ® HIV-1 v2.0 (“bioMérieux”), Siemens Versant: HIV-1 RNA 1.0 kPCR Assay 
(“Versant”), and Roche Molecular Systems: COBAS® AmpliPrep/COBAS® TaqMan® 
HIV-1 Test version 2.0 with the SPEX protocol (“Roche SPEX”) and the free virus 
elution protocol (“Roche FVE”).  The DBS accuracy measurements were reported by 
Vojnov et al. at the Clinton Health Access Initiative with the exception of Roche FVE, 
which was reported by Carmona and Mahlumba (Vojnov et al. 2014; Carmona and 
Mahlumba 2014; World Health Organization 2014).  All viral load assays were all 
compared at the 1,000 copies/mL cutoff (World Health Organization 
2014).  Accuracies of these assays are reported in Table 2. 
 
Cost 
The model makes simple assumptions about cost in order to maximize 
decision-making and minimize error, given informal cohort cost 
estimates.  Individuals on ART are expected to make a clinical visit every three 
months at a cost of about $20 (four visits per year for $80) (Siapka et al. 2014).  This 
cost is inclusive of CSM, as a clinic visit was assumed to be necessary for patients to 
pick up their medications.  CD4 count tests were not assumed to be part of the clinic 
visit by default, and were priced at $24 (Hyle et al. 2014), though projected CD4 was 
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reported as part of the model, regardless of whether testing was 
incorporated.  Annual drug cost is assumed to be $113 per year for a patient on first-
line therapy and $321 per year for a patient on second-line therapy (Clinton Health 
Access Initiative 2015). 
PVL and DBS testing are both assumed to cost $22 (Medecins Sans Frontieres 
2014), though sample collection for PVL costs an additional $3 for phlebotomy and 
transport, bringing the total testing cost to $25 for PVL and $22 for DBS (Medecins 
Sans Frontieres 2014).  All prices are converted to 2015 USD, and given the 
abbreviated time frame for this analysis, no additional discount rate has been 
applied and medicines are assumed to be generic (Clinton Health Access Initiative 
2015).  Cost outcomes are reported at the cohort level (with minimum significant 
figures) and are not broken down individually past the parameter input step.  Cost 
parameters are reported in Table 3. 
 
Sensitivity Analysis 
Four sensitivity analyses were performed.  A one-way sensitivity analysis 
was performed to measure the effect of varying assumed DBS viral load sensitivity 
from 80% to 100% in increments of 5%.  Any incident that precluded a treatment 
failure test (e.g. loss to follow-up or loss of sample) could also be considered a part 
of the sensitivity assumption.  These incidents lead to the same outcome as an 
insensitive test, they result in the assumption of maintenance on whatever 
treatment line the patient was on. 
 A second one-way sensitivity analysis was also performed to measure the 
effect of varying assumed DBS viral load specificity from 80% to 100% in 
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increments of 5%.  Observed specificities varied greatly in commercial assays 
(World Health Organization 2014), and this provided a way to visualize the change 
incrementally. 
 A third one-way sensitivity analysis was performed to measure the effect of 
varying assumed line switching due to ART intolerance or side-effects per follow-up 
period (from 0% to 10% in increments of 2%).  This was performed for both DBS 
and PVL to evaluate possible differences in effects between the two tests. 
 A two-way sensitivity analysis was performed to measure the effects of 
varying assumed DBS viral load sensitivity and specificity from 80% to 100% in 
increments of 5%.  This analysis offers fairly granular visualization of changes in 
both screening accuracy parameters. 
 
Software 







Deaths, sorted by treatment failure test, are shown in Figure 3a, cumulative 
for the cohorts of 10,000 ART naïve and 10,000 ART experienced patients at the end 
of 5 years of follow-up.  Incremental deaths (compared with CSM), are shown in 
Figure 3b.  DBS and PVL both resulted in dramatically fewer deaths in the cohort 
compared with CSM.  DBS was 91% as effective as PVL at averting deaths in the ART 
naïve cohort and 85% as effective in the ART experienced cohort, compared with 
CSM. 
Deaths, sorted by commercial DBS viral load assay, are shown in Figure 3c, 
cumulative for the cohorts of 10,000 ART naïve and 10,000 ART experienced 
patients at the end of 5 years of follow-up.  Some tests appeared to outperform the 
chosen baseline DBS viral load test with regard to averted deaths, others appeared 
to perform poorly. 
 
Secondary Outcomes 
Cumulative misclassifications, sorted by treatment failure test, are shown in 
Figure 4a, cumulative for the cohorts of 10,000 ART naïve and 10,000 ART 
experienced patients at the end of 5 years of follow-up.  CSM and CD4 had an 
extremely high number of downclassifications in both cohorts.  DBS viral load had a 
similar number of upclassifications as CSM in both cohorts.  Cumulative number 
virologically failing at the end of follow-up is shown in Figure 4b. 
Cumulative misclassifications, sorted by commercial DBS viral load assay, are 
shown in Figure 4c, cumulative for the cohorts of 10,000 ART naïve and 10,000 ART 
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experienced patients at the end of 5 years of follow-up.  Two assays had an 
extremely high number of upclassifications in both cohorts. 
 
Cost 
Overall cost and incremental cost compared with CSM, sorted by treatment 
failure test, are shown in Figure 5a, cumulative for the cohorts of 10,000 ART naïve 
and 10,000 ART experienced patients at the end of 5 years of follow-up.  Overall cost 
for DBS, PVL, and CD4 were similar among all cohorts. 
Incremental cost per death averted, compared with CSM, are shown in Figure 
5b.  Incremental cost per death averted for CD4 in both cohorts was more than 
$25,000, whereas PVL and DBS were both about $4,000 for the ART naïve cohort, 
and $10,000 to $15,000 for the ART experienced cohort. 
 
Sensitivity Analysis 
There were an additional 20-30 deaths per 10,000 people among the ART 
naïve and an additional 5-10 per 10,000 people among the ART experienced over 5 
years for each 5% decrease in sensitivity, while holding specificity constant, shown 
in Table 4a.  There were an additional 5-30 deaths per 10,000 people among the 
ART naïve and an additional 5-15 per 10,000 people over 5 years for each 5% 
decrease in sensitivity, while holding sensitivity constant, shown in Table 4b. 
There were an additional 20-30 downclassifications among the ART naïve 
and an additional 30-40 per 10,000 people among the ART experienced over 5 years 
for each 5% decrease in sensitivity, while holding specificity constant, shown in 
Table 4c.  There were an additional few hundred upclassifications per 10,000 people 
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among both the ART naïve and ART experienced over 5 years for each 5% decrease 
in sensitivity below 95%, while holding specificity constant, shown in Table 
4d.  Upclassification rate was unchanged by changes in sensitivity, 
downclassification rate was mostly unchanged by changes in specificity. 
There were an additional 30 deaths per 10,000 people among the ART naïve 
and an additional 20 per 10,000 people among the ART experienced over 5 years for 
each 2% increase in switch rate per follow-up period due to ART intolerance or 
side-effects, shown in Figures 7a and 7b. 
Changes in deaths, varying both sensitivity and specificity, are shown in 
Table 4a and 4b for the ART naïve and ART experienced respectively.  Changes in 
upclassifications, varying both sensitivity and specificity, are shown in Table 4e and 
4f for the ART naïve and ART experienced respectively. 
Changes in downclassifications, varying both sensitivity and specificity, are 
shown in Table 4c and 4d for the ART naïve and ART experienced 
respectively.  There were slightly fewer downclassifications as specificity decreased. 
Changes in programmatic cost, varying both sensitivity and specificity, are 
shown in Table 4g and 4h for the ART naïve and ART experienced 
respectively.  Crude cost estimates were more affected by changes in specificity than 
sensitivity.  Each 5% decrease in sensitivity led to a maximum increase of $100,000 
in programmatic cost, whereas each 5% decrease in specificity led to an increase of 
$100,000 to $300,000 in programmatic cost for the ART experienced.  On the other 
hand, for the ART naïve, the same effect of specificity was seen, but costs decreased 





The simulation performed here reiterates that PVL and DBS are superior 
across all outcomes, though add additional cost, considering CSM may be a part of 
the standard visit to pick up medication refills already.  For the additional cost, they 
provide a lot of life-saving potential (via timely switching to second-line 
therapy).  This is especially true among the ART naive, where the marginal cost per 
death averted is fairly low. 
Furthermore, DBS appears to be an acceptable alternative to PVL, costing 
only slightly more and resulting in only slightly poorer clinical outcomes.  Though it 
results in some misclassification (something PVL was assumed in this model to not 
do), the outcomes are drastically better than either CSM or CD4.  Treatment 
experience should be considered when deciding to implement viral load monitoring 
at the community level.  ART experienced groups have better outcomes in general, 
and are predicted to have a smaller margin for improvement from added virologic 
testing than the ART naïve.  Deleterious primary and secondary outcomes were less 
frequent and costs were lower overall among the ART experienced cohort.  In a 
setting where a larger proportion of the population is already enrolled in ART 
follow-up, it may be less important for those individuals to monitor viral 
loads.  There is still a case to be made that if the ART naïve patients are being put on 
viral load monitoring, ART experienced should be as well (because it is therefore 
available and already known to be outcome-optimal). 
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An additional concern at the community level is viral non-suppression.  Both 
upclassification and downclassification lead to greater risk of complete virologic 
failure, since patients on second-line therapy have 4 times the probability of 
virologic failure compared with those on first line therapy (Fox et al. 2012; Ajose et 
al. 2012).  This model does not account for transmission, which is mostly prevented 
when viral loads are suppressed, but is a major community risk from unsuppressed 
individuals, who transmit most when they have high viral load (Wood et al. 2014; 
Hamers et al. 2012).  This notable exemption from the model leads to a conservative 
estimate of the importance of viral load monitoring. 
For all of these reasons, in addition to decreased risk of ART resistance 
(something not evaluated in this model), the WHO recommends viral load 




This analysis does not constitute a rigorous, formal cost-effectiveness 
analysis.  There is no incremental cost-effectiveness ratio calculated, nor cost 
adjustments made for loss to follow-up, quality of life, opportunistic infections, ART 
regimen adherence, or any other personalized factors.  These aggregated cost 
estimates are not meant be highly precise, or to apply directly to a clinic or country, 
they are meant to serve as a generally informative tool (with numbers realistically 
“in the same ballpark”). 
Cost projections from the model do support a more rigorous cost-
effectiveness analysis which found that viral load monitoring was likely to be cost 
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effective in resource-limited settings compared with CSM and CD4 monitoring (A. 
Phillips et al. 2015).  Phillips et al. did not compare DBS to PVL, the current gold 
standard (though it projected costs for the latter), but they found that viral-load-
informed differentiated care lead to a greater switch rate (i.e. people were more 
able to switch lines of treatment when a line failed to virologically suppress), which 
subsequently lead to better health outcomes, that this type of differentiated care 
was cost effective, and that it was even cost saving when visit frequency was 
reduced for patients who were virally suppressed (A. Phillips et al. 2015).  Cost-
savings makes sense when comparing the lower cost of testing to the higher cost of 
clinical visits.  Others have expressed a similar encouragement for reducing the 
frequency of CD4 measurement for virally suppressed individuals (Hyle, Sax, and 
Walensky 2013; Girard et al. 2013; Gale et al. 2013; Shen et al. 2016). 
CSM was still found to be substantially cheaper than either DBS or PVL for 
treatment monitoring, but it produced far worse clinical outcomes.  Each option 
needs to be weighed on a contextual basis.   Much of this cost gap can be attributed 
to the higher price of second-line therapy, and individuals on CSM have a lower 
probability of being indicated by CSM to switch.  Most importantly, this research 
supports the assertion that DBS viral load monitoring is only marginally more 
expensive than PVL when including the cost of PVL transport and phlebotomy 







Underestimation of sensitivity assumed can be used as a crude stand-in for 
other processes in the test-and-treat system, including failure to follow-up, delays in 
results, and sample loss in transportation or storage.  Lower sensitivity, would 
result in the same outcome as a negative test: no change in treatment line, 
regardless of whether it is a downclassification.  But test downclassifications are a 
rarer outcome than upclassifications, because a downclassification requires two 
consecutive false negatives (a very low probability).  As specificity decreases, it 
becomes increasingly easier for an individual to test false positive twice 
consecutively.  This is concerning, especially for DBS viral load testing, where false 
positives at very low viral loads may be more likely (Monleau et al. 2010; 
Bertagnolio et al. 2010; Garrido et al. 2009; Arredondo et al. 2012).  Increasing the 
viral load cutoff for a positive test to 5000 copies/mL, rather than the 1000 
copies/mL as recommended by the WHO and used in this study, might alleviate this 
concern (Balinda et al. 2016; Fajardo et al. 2014). 
Given that intolerance did not impact PVL and DBS cohorts differentially, it 
seems as if it is not a particularly important phenomenon to model for 
comparison.  It is likely much more important for cost projection. 
 
Misclassification 
 Readers and clinicians need to have a discussion about what type and levels 
of misclassification (among other deleterious outcomes) are tolerable to 
them.  Lower sensitivity results in greater numbers of downclassifications and 
lower specificity results in greater numbers of upclassifications.  This analysis might 
20 
 
show that specificity is more important for two reasons.  First, because the 
downclassifications happen at a much lower rate than upclassifications and vary 
more readily with changes in their key parameter.  Second, because the costs of 
upclassification are much greater at the full cohort level.  This is a comparison from 
a public health level, and does not evaluate what the differential impact is on death 
(nor the value of death).  Upclassifications impact society more and 
downclassifications impact individuals more.  Even so, downclassifications can be 
corrected.  A downclassification can be uncovered in future treatment monitoring 
and the individual can have their ART line switched.  But an upclassification is 
permanent, because individuals cannot switch back on ART lines due to the likely 
emergence of resistance. 
 This discussion will also play into perceptions about the model used 
here.  Given the field of options of commercial DBS assays, the baseline sensitivity 
used here may be underestimated, but the baseline specificity used here may be 
overestimated.  If upclassification is a more serious issue, the model may be risky.  If 
upclassification is a less serious issue, the model may be overly conservative. 
 
Dried Blood Spots  
There are some logistical challenges of DBS.  Heat and humidity can put test 
reliability at risk (Monleau et al. 2010), and it requires a lab to do the actual 
analysis, even if a layperson can both draw and transport the sample.  But the 
advantages far outweigh these minor challenges. 
Viral load testing provides strong improvement in outcomes over CSM, with 
CD4 being an insufficient stand-in.  Four of the commercial DBS tests appear to be 
21 
 
sufficiently close in outcome to PVL as well: Abbott, Versant, bioMérieux, and Roche 
FVE.  If any of the DBS tests can get close to the 90/90 cutoff assumed here, it would 
be extremely favorable for cost/benefit ratio (i.e. cost per death averted) and 
reduction in adverse outcomes compared with CSM, especially in ART naïve cohorts, 
where the effect is greatest.  Good virologic monitoring is a front loading of cost, 
because the benefits of correct treatment classification reduce deleterious outcomes 
and may reduce individual costs, considering that the ART naïve cohorts become 
ART experienced cohorts, and net cost per person decreases as net outcomes 
improve. 
This conclusion echoes that of other recent studies (Templer et al. 2016; 
Balinda et al. 2016; Rutstein et al. 2015) and a recent systematic review (Smit et al. 
2014), which all found strong similarity between DBS viral load and PVL 
accuracy.  These other studies did not simulate, summarize, or compare the costs 
and outcomes of as many alternative monitoring strategies in one place, but they 
represent a body of recent literature that supports the use of DBS as necessary 
(World Health Organization 2014). 
 
Strengths 
This model was designed with transparency in mind.  The parameters were 
fairly simple and assumptions fairly limited.  This model can and should be modified 
to fit the needs of the decision-making settings. 
What is best for each clinic can and should be evaluated on a case-by-case 
(setting-by-setting) basis.  In places where there is access for PVL, PVL should be 
used if possible.  In places where there is no access for PVL, DBS is likely good 
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enough.  Clinics do not have to choose one or the other, they can mix.  The key is that 
viral load treatment monitoring is not one-size-fits-all, and clinics should make 
decisions based on what is affordable and feasible, and what is best for their 
patients.  This model is an attempt to project cost and clinical outcomes so that 
these decisions can be weighed with more information. 
 
Limitations 
This model makes an assumption that the underlying processes of HIV viral 
load testing and disease progression follow the Markov property, that disease states 
are independent.  This may or may not be true in reality.  Sensitivity and specificity 
may be dependent on viral load, rather than being the same across all cases (A. 
Phillips et al. 2015).  Phillips et al. were not alone in this supposition, and the 
dependency, if real, is most exaggerated at the breakpoint of 
upclassification/downclassification (Fox et al. 2012; Laprise et al. 2013; Garrido et 
al. 2009; Monleau et al. 2010; Templer et al. 2016; Arredondo et al. 2012; Balinda et 
al. 2016).  Furthermore, if true, this violates the Markov property, though the degree 
to which this model as a whole would be rendered inaccurate is unknown. 
This model also needs to be modified in order for the results to apply most 
appropriately to a given context.  If one clinic only has access to certain tests and 
medications with different costs and sensitivity/specificity parameters, they cannot 
follow the base case analysis here, they need to redo the analysis with modified 
parameters.  And despite the strides toward “simplicity”, there is still the concern 
that the model is not understandable enough.  The audience should not just be 
health researchers with formal statistical training, but health practitioners as well, 
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who may lack such training.  The model has not been deployed to any sorts of field 
tests or focus groups so there is no real answer to that question. 
There are also real concerns about the validity of some of the 
parameters.  Switch rate, which is assumed here to be 100%, is not going to be 
perfect in practice.  This means that regardless of the amount of cases correctly 
identified as treatment failure, some people will in effect be downclassified by not 
changing treatment lines.  The DBS viral load accuracy parameters, gained from 
systematic reviews by Vojnov, Carmona and Mahlumba, are unpublished and are 
cited only by the World Health Organization (World Health Organization 2016). 
Additionally, the available treatments and guidelines for treatment would 
affect the underlying distribution of HIV-infected individuals and their transition 
properties, which could leave the parameters used here outdated.  Over time, if 
UNAIDS-predicted trends continue (UNAIDS 2016), and more people adopt WHO 
treatment guidelines (World Health Organization 2016), there will be fewer and 
fewer ART naïve individuals and the gains of implementing DBS will be fewer. 
Finally, and most of all, the cohorts studied here are simulated, not 
“real”.  They are extrapolated and built upon by real data, but they are not subject to 
unpredictability of real people or strength of a prospective clinical or cohort 
trial.  This simulation is predetermined, and does not capture that type of variability. 
 
Further Development 
Widening the scope of applicability is the natural starting point for advancing 
HIV treatment.  Viral load monitoring systems need to expand to capture more of 
the population, clinical and immunologic monitoring are insufficient.  Viral load-
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informed differentiated care, as modeled here, can save money and lives.If we are to 
ever meet the 90-90-90 goal (“90-90-90: An Ambitious Treatment Target to Help 
End the AIDS Epidemic” 2014), we will need better assays with wider 
availability.  As far as this type of model, a multiple cohort comparison of different 
treatment monitoring methods would go a long way toward validating (or 





The Markov state-transition model used here, which followed simulated 
cohorts of ART naïve and experienced sub-Saharan African adults, found DBS viral 
load monitoring to attain similar clinical outcomes and costs to PVL.  These results 
reinforce that DBS is an appropriate viral load monitoring method where PVL is not 
available, even when assuming conservative accuracy figures.  Clinical symptoms 
monitoring costs less and is easier to perform, but results in poorer health outcomes 
for patients, including inappropriate switching to more expensive second-line 
therapy, failure to switch when first-line therapy has failed, reduced likelihood of 
viral suppression, and increased risk of death.  Further research is necessary to 
validate some of the assumptions made by the model, but outcomes appear to be 
consistent with other recent research, and the structure and is easier to understand, 





Supplement 1. Overview of the Current State of Treatment Monitoring 
The World Health Organization recently released their “Consolidated 
Guidelines on The Use of Antiretroviral Drugs for Treating and Preventing HIV 
Infection” (2nd edition), which recommends for the first time (for the WHO) that all 
people living HIV should receive treatment (antiretroviral therapy) (World Health 
Organization 2016).  Routine viral load testing has been recommended as the ideal 
for diagnosing treatment failure (World Health Organization 2014; World Health 
Organization 2016).  Viral load monitoring is newer than CD4 monitoring, now 
aimed at replacing it and supplementing CSM for determining treatment failure 
(World Health Organization 2016), but it has faces major logistic challenges, 
especially with requirements for plasma viral load (Neogi et al. 2011; Madec et al. 
2013; Fajardo et al. 2014). 
Ten studies (Laurent et al. and Boyer et al. followed the same study) (Laurent 
et al. 2011; Boyer et al. 2013) on the mortality under different methods or tests for 
virologic failure were included in Supplement S1, spanning publication dates from 
2008 to 2015.  At minimum, some prior studies found viral load monitoring 
methods were non-inferior to CSM and CD4 for survival (Tucker et al. 2014; 
Jourdain et al. 2013; Mermin et al. 2011; A. N. Phillips et al. 2008).   Most concluded 
that they offered superior survival rates (Laurent et al. 2011; Ingole et al. 2013; 
Shen et al. 2016; A. Phillips et al. 2015; Chaiwarith et al. 2007; Mee et al. 2008).  In 
addition to inferior survival, CSM alone and CD4 count measurement are not 
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sufficient for determining treatment failure (Ferreyra et al. 2012; Rutherford et al. 
2014; Rawizza et al. 2011). 
Inability to (quickly) determine treatment failure leads to extended time with 
unsuppressed viral load (Calmy et al. 2007).  This is important because cumulative 
time with unsuppressed viral load (also known as “viremia copy-years”) is 
positively associated with morbidity and mortality (Cole et al. 2010; Mugavero et al. 
2011).  Both CSM and CD4 are likely to eventually detect treatment failure, as 
unsuppressed viral load would lead to deteriorating health and HIV-related sequela, 
but it would be beneficial to determine failure before these individual outcomes 
emerge. 
There are also broader concerns of transmission and resistance.  Individuals 
with unsuppressed viral replication will transmit HIV at a greater rate, posing a risk 
to the community (Hall et al. 2013; Calmy et al. 2007).  Furthermore, unsuppressed 
viral load leads to the emergence of drug resistance (Gupta et al. 2009; Bangsberg 
2008; Calmy et al. 2007).  Drug resistance of an individual’s HIV infection 
jeopardizes their future treatment options, especially in resource-limited settings 
where there may be fewer lines of treatment available.  Drug resistance of an 
individual’s HIV infection may also lead to spread of community drug resistance if 
they transmit to others.  Viral load monitoring provides a way to combat these risks 
(Calmy et al. 2007; Hall et al. 2013; Gupta et al. 2009; Bangsberg 2008). 
Most of all, viral load monitoring measures most directly the results (and 
success, or lack thereof) of treatment.  The goal of treatment is to suppress viral 
replication.  Clinical and immunologic monitoring may detect the result changes in 
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viral load, but they do not measure viral load.  If we want to know if treatment is 
working, conceptually, the best way to evaluate that is measuring whether the virus 
is successfully reproducing at a high rate. 
Prior simulations found viral load to compare favorably to both CSM alone 
and CD4 for treatment failure.  In 2008, Phillips et al. found viral load monitoring to 
lead to the greatest survival, though not cost savings (A. N. Phillips et al. 2008).  In 
2012, Hamers et al. found viral load monitoring to lead to the greatest survival and 
cost savings, when used at 6 month intervals (compared to CD4 count at 6 month 
intervals, though not at 12) (Hamers et al. 2012).  Most recently, in 2015, Phillips et 
al. found viral load (specifically DBS) monitoring to lead to the lowest death rate and 
incidence of HIV, as well as improvement in disability adjusted life years with higher 
switch rates (A. Phillips et al. 2015).  Phillips et al. additionally found likely cost 
effectiveness with the use of viral-load-informed differentiated ART care with DBS 
viral load testing (A. Phillips et al. 2015). 
The analysis provided in the main write-up primarily aims to evaluate how 
effectively DBS can be used in place of PVL and follow-up the prior simulation 





Supplement 2. Parameter Revisions 
In the process of constructing this analysis, a literature search was 
performed to update parameters in the model as necessary.  The model presented in 
this manuscript was originally constructed by Mark Moses and David Dowdy, and 
first presented in May 2015 as “Costs and Consequences of Viral Load Monitoring 
with Dried Blood Spots versus Plasma in Resource-Limited Settings”, a report for 
the World Health Organization HIV Treatment Guidelines Development 
Committee.  Though the searches were neither automated, nor exhaustive, this 
model has been adapted and modified substantially for 2016, following an updated 
review of the literature. 
 
This review was intended to update or verify values for the following parameters: 
 CSM, CD4, and DBS treatment failure accuracy 
 Side effects rate 
 Viral suppression rate (first line, second line, and first line in the first 
6 months) 
 State transition by CD4 states (suppressed upwards, unsuppressed 
downwards) 
 Mortality by CD4 states 
 Initial distribution of CD4 states (ART naive) 
 Cost (first line ART, second line ART, PVL, DBS, CSM/clinic) 
 
Supplement Review S1 pertains to mortality parameters for patients in CSM, 
CD4, DBS, and/or PVL treatment monitoring.  Supplement Review S2 pertains to 
testing accuracy parameters, and summarizes selected studies which reported 
sensitivity and specificity for CSM, CD4, and/or DBS treatment failure 
assessments.  Cost, initial distributions, side effect rates, and state transitions were 
not listed in either table due to insufficient sources for comparison.  This does not 





Studies to inform the performance of each mode of treatment monitoring 
were required to report accuracy parameters (sensitivity or specificity values), 
location (South America, Africa, and Asia only, to maximize representativeness for 
resource-limited settings), recency (published in the past 10 years, enrolling 
patients in the past 15 years), mortality rates, and/or threshold of detection (1,000-
5,000 copies/mL for viral load threshold only, if reported, as lower values resulted 
in unreasonably low sensitivity). 
 
Literature Review Search Process 
The databases searched were PubMed and Google Scholar.  There were no 
specific journals selected for or searched.  Searches took place between May and 
July 2016. 
Keyword search terms: 
 Dried Blood Spots | DBS 
 Plasma | PVL 
 Clinical Symptoms 






 Viral Load (Monitoring) 
 CD4 (Count) (Monitoring) (Evolution) 
 Treatment (Failure) (Monitoring) 
 Virologic (Failure) | VF 
 (Sub-Saharan) Africa | Resource-Limited 
 
Keywords in parentheses “( )”, were used in conjunction with keywords in 
their row (e.g. ‘Africa’ and ‘Sub-Saharan Africa’ were searched terms, but not ‘sub-
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Saharan’).  Numerous parenthetical keywords were often used together (e.g., ‘CD4 
count monitoring’ or ‘CD4 count evolution’).  Keywords after the pipe, “|”, were used 
as alternates for keywords in their row (e.g. ‘Dried Blood Spots’ and ‘DBS’ were 
searched terms, but never together).  Joining multiple piped and parenthetical terms 
generated complete (and often broad) keyword search strings like ‘Dried Blood 
Spots Viral Load Treatment Monitoring Sub-Saharan Africa’. 
Relevant literature was cataloged in the Paperpile reference manager on 
Google Chrome.  Basic information on this literature was transferred to a 
spreadsheet in Microsoft Excel 2016 for quick access to reference summaries.  The 
most relevant papers were then expanded into tables in this supplement for ease of 
reading and evaluation.  Summary information includes first author, journal, year of 
publication, type, location, size, outcomes (from results), and conclusion(s) of the 
studies.  Not all references cited in the complete analysis are included in these 
tables. 
Many of these study results were not incorporated directly into the model, 
but were used to fulfill the literature review’s second purpose in informing the 
hypothesis that DBS was a sufficient substitute for PVL and that both were superior 
to CD4 and CSM (*for health outcomes).  Some of this evidence is presented in S2, 
based on comparative accuracy measurements, and some is presented in S1, based 






Summary and Model Updates 
Eight studies on the accuracy of different methods or tests for virologic 
failure were included in Supplement S2, spanning publication dates from 2007 to 
2015.  The primary finding of these studies was that CD4 immunologic criteria for 
virologic failure were as good or better than clinical symptoms monitoring criteria 
for virologic failure, with accuracy of clinical symptoms monitoring in the 10-15% 
sensitivity, 80-100% specificity range, and CD4 count monitoring in the 25-35% 
sensitivity, 80-100% specificity range.  Neither the immunologic nor the clinical 
symptoms monitoring failure assessment performed better than virologic testing in 
predicting virologic failure and determining treatment failure.  Additionally, dried 
blood spot viral load testing produced similar accuracy results to plasma viral load 
testing in most scenarios in the 85-100% sensitivity, 85-100% specificity range 
(Napierala Mavedzenge et al. 2015; World Health Organization 2016; A. Phillips et 
al. 2015) (with notable exceptions being the low specificity of two of the commercial 
assays found in Vojnov et al.’s systematic review) (World Health Organization 
2016).  The previous iteration of this simulation used a 95% sensitivity and 90% 
specificity, but the current iteration uses a 90% sensitivity and 90% specificity as 
baseline DBS accuracy values.  This is probably an underestimation of sensitivity 
and a slight overestimation of specificity, given the commercial values from Vojnov 




Values for some other parameters, including state transition probabilities 
remained unchanged due to lack of data that fit the structure of the model 
(primarily due to the state categories not matching). 
For cost updates, the Clinton Health Access Initiative’s “ARV Market Report”, 
dated November 2015 and cited by the WHO and others, was used to determine 
first-line and second-line ART pricing (Clinton Health Access Initiative 2015).  The 
CHAI report provided an “average” cost for both lines in resource-limited generic-
accessible countries of $113 for first-line and $321 for second-line therapies (both 
per person year) (Clinton Health Access Initiative 2015).  The most up-to-date 
pricing available was from Medecin Sans Frontiere’s “Untangling the Web of ARV 
Price Reductions”, whose newest edition was dated July 2016 (Medecins Sans 
Frontieres 2016).  The MSF report provided a “lowest” cost and specified a regimen-
by-regimen cost, with a first-line of TDF/FTC/EFV priced at $100 and a second-line 
of AZT/3TC/ATV/r priced at $286 (both per person year) (Medecins Sans 
Frontieres 2016).  The choice to compromise for a set average or estimated value 
for the simulation was made to allow for the most flexibility and is comparable to 
the choice to compromise for 90% sensitivity and 90% specificity on DBS testing 
parameters.  Using pricing MSF’s cheapest lines of choice is comparable to using the 
most accurate commercial DBS viral load assay, and it might also show favoritism 
toward a certain line (or assay).  It is less important that the numbers are perfectly 
accurate and more important that they are conservative and more broadly usable 
(especially for pricing). 
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Supplement Tables T1, T2, and T3 contain final model parameters and 
sources, with updated numbers marked and short notes on the updates 
below.  Some parameter values were simply recalculated due to error or 
modification of parameters they were dependent on.  Some sources were changed to 
reflect the primary source rather than a secondary source, even if the value(s) 
remained unchanged. 
Again, this literature review was not exhaustive and does not contain all 
literature evaluated but excluded from model use.  Some parts of the model were 
built around specific parameters that would not be retrievable in usable form 
without substantial redesign, like Mellors et al.’s and Gabillard et al.’s CD4 state 
transition probabilities (Mellors et al. 1997; Gabillard et al. 2013).  But updates were 
made to treatment transition probabilities, mortality probabilities, initial CD4 count 
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Table 1. Base case Markov model epidemiological parameters  
 
Parameter Value Source 
    
Treatment Transition Probabilities   
 1st line ART failure, first 6 months 21% Barth et al. 2010 
 1st line ART failure, after 6 months 2% Fox et al. 2012 
 2nd line ART failure 8% Ajose et al. 2012 
    
CD4 State Transition Probabilities   
 <100 to 100-199 cells/mm3 45% Gabillard et al. 2013 
 100-199 to 200-350 cells/mm3 18% Gabillard et al. 2013 
 200-350 to >350 cells/mm3 10% Gabillard et al. 2013 
    
 >350 to 200-350 cells/mm3 22% Mellors et al. 1997 
 200-350 to 100-199 cells/mm3 22% Mellors et al. 1997 
 100-199 to <100 cells/mm3 31% Mellors et al. 1997 
    
CD4 Count Distribution Among ART Naïve   
 CD4 >350 cells/mm3 12% IHME 2015* 
 CD4 200-350 cells/mm3 30% IHME 2015* 
 CD4 100-199 cells/mm3 27% IHME 2015* 
 CD4 <100 cells/mm3 31% IHME 2015* 
    
CD4 Count Distribution Among ART Experienced   
 CD4 >350 cells/mm3  48% Calibrated from ART Naïve** 
 CD4 200-350 cells/mm3  36% Calibrated from ART Naïve** 
 CD4 100-199 cells/mm3  11% Calibrated from ART Naïve** 
 CD4 <100 cells/mm3  4% Calibrated from ART Naïve** 
    
Probability of Death   
 CD4 >350 cells/mm3  <1% Maduna et al. 2015 
 CD4 200-350 cells/mm3  1% Maduna et al. 2015 
 CD4 100-199 cells/mm3  2% Maduna et al. 2015 
 CD4 <100 cells/mm3  2% Maduna et al. 2015 
    
     
 
* Institute for Health Metrics and Evaluation (IHME) 
** Initial distribution of CD4 states of the cohort of ART experienced patients was 
calibrated at entry to the CD4 count distribution of ART naïve patients who were on 




Table 2. Base case screening accuracy parameters  
 
Parameter Sensitivity Specificity Source 
     
Screening Accuracy    
 CSM 11% 90% Rutherford et al. 2014 
 CD4 27% 86% Rutherford et al. 2014 
 PVL 100% 100% Assumed 
 DBS* 90% 90% Assumed 
 DBS (Abbott) 95% 92% Vojnov et al. 2014 
 DBS (Biocentric) 95% 55% Vojnov et al. 2014 
 DBS (bioMérieux) 84% 95% Vojnov et al. 2014 
 DBS (kPCR) 91% 88% Vojnov et al. 2014 
 DBS (Roche, SPEX protocol) 99% 44% Vojnov et al. 2014 
 DBS (Roche, FVE protocol) 81% 97% Carmona and Mahlumba 2014 
     





Table 3. Base case cost parameters (measured in USD)  
 
Parameter Cost Source 
    
 Annual First-line ART Regimen per patient $113 CHAI 2015 
 Annual Second-line ART Regimen per patient $321 CHAI 2015 
 DBS Screen $22 MSF 2014 
 PVL Screen $25 MSF 2014 
 CD4 Screen $24 Hyle et al. 2014 
 Clinic Visit $20 Siapka et al. 2014 
    






Table 4a. Number of deaths among 10,000 ART naive patients after 5 years of 




Table 4b. Number of deaths among 10,000 ART experienced patients after 5 years 








100% 95% 90% 85% 80%
100% 1590 1611 1634 1661 1692
95% 1596 1616 1639 1666 1697
Specificity 90% 1611 1630 1653 1680 1711
85% 1635 1655 1677 1703 1734
80% 1669 1688 1709 1735 1764
Sensitivity
100% 95% 90% 85% 80%
100% 678 683 688 694 701
95% 682 686 691 697 704
Specificity 90% 692 696 701 707 714
85% 709 713 718 724 731




Table 4c. Number of downclassifications among 10,000 ART naive patients after 5 




Table 4d. Number of downclassifications among 10,000 ART experienced patients 








100% 95% 90% 85% 80%
100% 0 23 50 82 121
95% 0 23 50 81 120
Specificity 90% 0 22 48 78 116
85% 0 21 45 74 110
80% 0 19 41 68 101
Sensitivity
100% 95% 90% 85% 80%
100% 0 32 68 111 161
95% 0 31 68 110 159
Specificity 90% 0 30 66 107 154
85% 0 29 62 101 147




Table 4e. Number of upclassifications among 10,000 ART naive patients after 5 




Table 4f. Number of upclassifications among 10,000 ART experienced patients after 







100% 95% 90% 85% 80%
100% 0 0 0 0 0
95% 62 62 62 62 62
Specificity 90% 243 243 243 243 243
85% 528 528 528 528 528
80% 895 895 895 895 895
Sensitivity
100% 95% 90% 85% 80%
100% 0 0 0 0 0
95% 74 74 74 74 74
Specificity 90% 292 292 292 292 292
85% 637 637 637 637 637




Table 4g. Overall costs for 10,000 ART naive patients after 5 years of follow-up, 





Table 4h. Overall costs for 10,000 ART experienced patients after 5 years of follow-







100% 95% 90% 85% 80%
100% $9.7 $9.7 $9.7 $9.6 $9.6
95% $9.7 $9.7 $9.7 $9.6 $9.6
Specificity 90% $9.8 $9.8 $9.8 $9.8 $9.7
85% $10.0 $10.0 $10.0 $10.0 $9.9
80% $10.3 $10.3 $10.3 $10.2 $10.2
Sensitivity
100% 95% 90% 85% 80%
100% $9.0 $9.0 $9.1 $9.1 $9.1
95% $9.1 $9.1 $9.1 $9.1 $9.2
Specificity 90% $9.2 $9.2 $9.3 $9.3 $9.3
85% $9.5 $9.5 $9.5 $9.5 $9.6
80% $9.8 $9.9 $9.9 $9.9 $9.9
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Figure 1. Set of feasible Markov states and transitions as a result of virologic 




Note: this model assumes no third-line (or other) treatment is available, therefore no 


















Figure 3a. Deaths among 10,000 ART naïve and experienced patients after 5 years of  




Screening Method PVL DBS CSM CD4 
Sensitivity 100% 90% 11% 27% 
Specificity 100% 90% 91% 86% 
Deaths (ART Naïve) 1591 1653 2317 2229 

































Figure 3b. Incremental deaths (compared with CSM) among 10,000 ART naïve and  




Screening Method PVL DBS CD4 
Sensitivity 100% 90% 27% 
Specificity 100% 90% 86% 
Deaths Averted (ART Naïve) 727 664 89 


































Figure 3c. Deaths among 10,000 ART naïve and experienced patients after 5 years of  





























Screening Method Abbott Biocentric bioMerieux Versant Roche SPEX Roche FVE
Sensitivity 95% 95% 84% 91% 99% 81%
Specificity 92% 55% 95% 88% 44% 97%
Deaths (ART Naïve) 1623 1942 1670 1658 2065 1687
Deaths (ART Experienced) 692 923 699 707 1030 701
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Figure 4a. Up- and downclassification among 10,000 ART naïve and experienced patients  




Screening Method PVL DBS CSM CD4 
Sensitivity 100% 90% 11% 27% 
Specificity 100% 90% 91% 86% 
Downclassifications (ART Naïve) 0 48 1571 1218 
Downclassifications (ART Experienced) 0 66 1152 950 
Upclassifications (ART Naïve) 0 243 220 470 







































Figure 4b. Number virologically failing (viral load above 1,000 copies/mL) among 10,000  




Screening Method PVL DBS CSM CD4 
Sensitivity 100% 90% 11% 27% 
Specificity 100% 90% 91% 86% 
Virologically Failing (ART Naïve) 953 1061 1720 1636 




































Figure 4c. Up- and downclassification among 10,000 ART naïve and experienced patients  










































Screening Method Abbott Biocentric bioMerieux Versant Roche SPEX Roche FVE
Sensitivity 95% 95% 84% 91% 99% 81%
Specificity 92% 55% 95% 88% 44% 97%
Downclassifications (ART Naïve) 21 8 85 41 0 112
Downclassifications (ART Experienced) 29 12 116 57 1 149
Upclassifications (ART Naïve) 170 2926 74 359 3453 26




Figure 5a. Cost and incremental cost (compared with CSM, in millions of 2015 US dollars)  





Screening Method PVL DBS CD4 
Sensitivity 100% 90% 27% 
Specificity 100% 90% 86% 
Cost (ART Naïve) $9.8 $9.8 $9.5 
Cost (ART Experienced) $9.2 $9.3 $9.8 
Incremental Cost (ART Naïve) $2.9 $2.9 $2.6 






























Incremental Cost (ART Naïve)




Figure 5b. Incremental cost per death averted (compared with CSM, in thousands of 2015  
US dollars) among 10,000 ART naïve and experienced patients over 5 years of follow-up,  




Screening Method PVL DBS CD4 
Sensitivity 100% 90% 27% 
Specificity 100% 90% 86% 
Incremental Cost per Death Averted (ART Naïve) $4.0 $4.3 $28.9 
Incremental Cost per Death Averted (ART Experienced) $10.0 $12.6 $328.0 
 
Note: incremental cost per death averted for was excessive in both cohorts for CD4, so the y- 
































Figure 6a. Deaths among 10,000 ART naïve and experienced patients after 5 years of  




Sensitivity 100% 95% 90% 85% 80% 
Specificity 90% 90% 90% 90% 90% 
Deaths (ART Naïve) 1611 1630 1653 1680 1711 






























Figure 6b. Deaths among 10,000 ART naïve and experienced patients after 5 years of  




Sensitivity 90% 90% 90% 90% 90% 
Specificity 100% 95% 90% 85% 80% 
Deaths (ART Naïve) 1634 1639 1653 1677 1709 





























Figure 6c. Up- and downclassification among 10,000 ART naïve and experienced patients  




Sensitivity 100% 95% 90% 85% 80% 
Specificity 90% 90% 90% 90% 90% 
Downclassified (ART Naïve) 0 22 48 78 116 
Downclassified (ART Experienced) 0 30 66 107 154 
Upclassified (ART Naïve) 243 243 243 243 243 






























Figure 6d. Up- and downclassification among 10,000 ART naïve and experienced patients  




Sensitivity 90% 90% 90% 90% 90% 
Specificity 100% 95% 90% 85% 80% 
Downclassified (ART Naïve) 50 50 48 45 41 
Downclassified (ART Experienced) 68 68 66 62 57 
Upclassified (ART Naïve) 0 62 243 528 895 



































Figure 7a. Deaths among 10,000 ART naïve and experienced patients after 5 years of  





Intolerance 0% 2% 4% 6% 8% 10% 
Deaths (ART Naïve) 1653 1685 1714 1743 1770 1796 




































Figure 7b. Deaths among 10,000 ART naïve and experienced patients after 5 years of  





Intolerance 0% 2% 4% 6% 8% 10% 
Deaths (ART Naïve) 1591 1625 1658 1690 1720 1748 


































Supplement Table T1. Base case Markov model epidemiological parameters  
 
  
Parameter Value Source 
    
Treatment Transition Probabilities   
 1st line ART failure, first 6 months* 21% Barth et al. 2010 
 1st line ART failure, after 6 months 2% Fox et al. 2012 
 2nd line ART failure** 8% Ajose et al. 2012 
    
CD4 State Transition Probabilities   
 <100 to 100-199 cells/mm3 45% Gabillard et al. 2013 
 100-199 to 200-350 cells/mm3 18% Gabillard et al. 2013 
 200-350 to >350 cells/mm3 10% Gabillard et al. 2013 
    
 >350 to 200-350 cells/mm3 22% Mellors et al. 1997 
 200-350 to 100-199 cells/mm3 22% Mellors et al. 1997 
 100-199 to <100 cells/mm3 31% Mellors et al. 1997 
    
CD4 Count Distribution Among ART Naïve   
 CD4 >350 cells/mm3 12% IHME 2015 
 CD4 200-350 cells/mm3 30% IHME 2015 
 CD4 100-199 cells/mm3 27% IHME 2015 
 CD4 <100 cells/mm3 31% IHME 2015 
    
CD4 Count Distribution Among ART Experienced   
 CD4 >350 cells/mm3 † 48% Calibrated from ART Naïve 
 CD4 200-350 cells/mm3 † 36% Calibrated from ART Naïve 
 CD4 100-199 cells/mm3 † 11% Calibrated from ART Naïve 
 CD4 <100 cells/mm3 † 4% Calibrated from ART Naïve 
    
Probability of Death   
 CD4 >350 cells/mm3 †† <1% Maduna et al. 2015 
 CD4 200-350 cells/mm3 †† 1% Maduna et al. 2015 
 CD4 100-199 cells/mm3 †† 2% Maduna et al. 2015 
 CD4 <100 cells/mm3 †† 2% Maduna et al. 2015 
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* Value changed from 18% to 21%.  Source changed from Achieng et al. 2012 to Barth 
et al. 2010. 
** Value changed from 2% to 8%.  It is unclear why this value was 2%. 
† Values changed from 57%, 36%, 6%, and 1% to 48%, 36%, 11%, and 4% 
respectively, following updates to treatment transition probabilities. 
†† Values changed from 1%, 1%, 2%, and 10% to <1%, 1%, 2%, 12% respectively.  
Source changed from Gabillard et al. 2013 to Maduna et al. 2015.  
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Supplement Table T2. Base case screening accuracy parameters 
 
Parameter Sensitivity Specificity Source 
     
Screening Accuracy    
 CSM 11% 90% Rutherford et al. 2014 
 CD4 27% 86% Rutherford et al. 2014 
 PVL 100% 100% Assumed 
 DBS* 90% 90% Assumed 
 DBS (Abbott)** 95% 92% Vojnov et al. 2014 
 DBS (Biocentric)** 95% 55% Vojnov et al. 2014 
 DBS (bioMérieux)** 84% 95% Vojnov et al. 2014 
 DBS (kPCR)** 91% 88% Vojnov et al. 2014 
 DBS (Roche, SPEX protocol)** 99% 44% Vojnov et al. 2014 
 DBS (Roche, FVE protocol)** 81% 97% Carmona and Mahlumba 2014 
     
      
 
* Sensitivity changed from 95% to 90%, no change in specificity. 





Supplement Table T3. Base case Markov model cost parameters 
 
Parameter Cost Source 
    
 Annual First-line ART Regimen per patient * $113 CHAI 2015 
 Annual Second-line ART Regimen per patient ** $321 CHAI 2015 
 DBS Screen $22 MSF 2014 
 PVL Screen $25 MSF 2014 
 CD4 Screen † $24 Hyle et al. 2014 
 Clinic Visit †† $20 Siapka et al. 2014 
    
     
 
* First-line regimen cost changed from $144 to $113.  Source changed from MSF 2014 
(“Unravelling the Web of ART Price Reductions”) to CHAI 2015 (“ARV Market Report”). 
** Second-line regimen cost changed from $288 to $321.  Source changed from MSF 
2014 (“Unravelling the Web of ART Price Reductions”) to CHAI 2015 (“ARV Market 
Report”). 
† CD4 screen cost added. 
†† Source changed to Siapka et al. 2014 from Phillips et al. 2015 to reflect primary 




Supplement Literature Review S1. Treatment Failure Test Mortality Parameters 
 













Deaths per 100py: 
5.85 with DBS, 
5.53 with CD4, 
7.5 with CSM 
“Our results suggest that viral-load-informed differentiated 
ART care, using DBS sampling if necessary, is likely to be 
cost-effective in low-income settings in sub-Saharan Africa 
and is a sustainable model for providing ART.” 








1.9 CSM vs CD4 
(year 1), 
1.0 CSM vs CD4 
(year 3), 
1.3 CSM vs PVL 
(year 1), 
1.0 CSM vs PVL 
(year 3). 
“Performing no VL tests in the first year after ART initiation 
was significantly associated with higher mortality 
rates.  CD4 cell counts can be reduced to twice during the 
first year of ART and be reduced or stopped for patients 
who have achieved virologic suppression or immunologic 
stability after 12 months of treatment.” 
Maduna et 
al. 






Mortality on ART 







“Rates of morbidity and mortality are lowest among those 
with CD4+ count of 350 or higher and rates do not differ for 
those with counts of 350–499 versus 500+ cells... Latest 
CD4+ specific death rates were greater for those not on ART 












1.36 CSM vs CD4, 
“CM + IM was shown to be beneficial in terms of a combined 
mortality and morbidity endpoint compared to CM alone. 
VM was associated with shorter duration of viremia and 
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1.10-1.72 CD4 vs 
CD4 + PVL, 
1.31-1.57 CSM vs 
CD4 + PVL 
higher rates of switching, but an impact on mortality was 
not consistently shown.” 
Gabillard 
et al. 









Mortality by CD4 









CD4 increase by 
CD4 count after 




“Death and AIDS rates remained substantial after ART 
initiation, even in individuals with high CD4 cell 
counts.  Death rates appeared comparable with those 











Deaths per 100py: 
1.8 with PVL + 
CD4, 
4.7 with CSM 
“Laboratory monitoring is not cost effective in Cameroon 
compared with clinical monitoring alone in the current 
context of fixed health-care budgets.  The cost-effectiveness 
of the laboratory strategy strongly improved in patients 
starting ART with a CD4 cell count of fewer than 200 cells 










Deaths per 100py: 
1.4 with PVL, 1.1 
with CD4 
“A CD4-based switching strategy was non-inferior in terms 
of clinical outcomes at 3 years of follow-up, compared to a 
reference VL based switching strategy. Moreover, at study 
end there were no differences in terms of viral suppression 















1.57 CSM vs PVL, 
1.43 CSM vs CD4, 
1.10 CD4 vs PVL 
“People in the CD4 cell count monitoring arm did better 
than those with clinical monitoring alone... We did not find 
that quarterly viral loads provided additional clinical 












1.31 CSM vs CD4 
“Clinical monitoring alone is not non-inferior to clinical 
monitoring plus laboratory monitoring in terms of mean 
increase in CD4 cell count to 2 years...  Survival at 24 







Africa Deaths per 100py: 
9.7 with CSM, 8.0 
with PVL 
“For patients on the first-line regimen… the benefits of viral 
load or CD4 cell count monitoring over clinical monitoring 
alone are modest. Development of cheap and robust 
versions of these assays is important, but widening access 
to antiretrovirals—with or without laboratory 



























“There was generally good agreement between DBS and 
plasma VL for detection of VL>1000. Overall, finger prick 
DBS appeared to be an acceptable sample for classifying 
VL as above or below 1000 copies/mL using the 
NucliSENS assay.” 





















“Some of the assay types were found to have low 
sensitivity at the time this evaluation was performed (up 
to June 2014) and should be avoided. While this reduced 
sensitivity means that plasma specimens are preferred 
for viral load testing, modelling suggests that if viral load 
testing with DBS specimens can be performed with 
reasonable sensitivity and specificity (>85%), then costs 
and outcomes are similar.” 
 
Note: both this and the following study by Carmona and 
Mahlumba have been cited in multiple WHO reports, but 
are unpublished.  The true date of the final study report 
appears to be 2014, but has been cited by the WHO as 












“Some of the assay types were found to have low 
sensitivity at the time this evaluation was performed (up 
to June 2014) and should be avoided. While this reduced 
sensitivity means that plasma specimens are preferred 
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for viral load testing, modelling suggests that if viral load 
testing with DBS specimens can be performed with 
reasonable sensitivity and specificity (>85%), then costs 


















“The 2010 WHO clinical and immunologic criteria are 
insensitive and have low PPV for predicting virologic 
failure. These data support the strong recommendation 
2013 treatment guidelines that viral load testing be used 
to monitor for, diagnose, and confirm ART failure.” 
Ferreyra et 
al. 










with CSM + CD4 
“Clinical and immunological criteria were found to 
perform relatively poorly in predicting virological 
failure of ART. VL monitoring and new algorithms for 
assessing clinical or immunological treatment failure, as 
well as improved adherence strategies, are required in 
ART programs in resource-limited settings.” 









“This analysis, which uses programmatic treatment data, 
a large sample size, longer duration of follow-up, and 
rates of virologic failure commensurate with other real-
life treatment cohorts in RLS, provides the strongest 
evidence to date of the poor performance of 
immunologic criteria in identifying treatment failure.” 










0.925 for CD4 
“Immunological criteria do not accurately predict 
virological failure resulting in significant 
misclassification of therapeutic responses. There is an 
urgent need for inclusion of viral load testing in the 
initiation and monitoring of ART.” 
Mee et al. AIDS, 2008 
(2002-2004) 




“WHO clinical and CD4 criteria have poor sensitivity and 
specificity in detecting virological failure… Individuals 








incorrectly classified as having treatment failure and 
unnecessarily switched to second-line therapy. 
Virological failure should be confirmed before switching 



















“Our study, which was limited by small numbers, was 
not able to demonstrate that immunological or clinical 
criteria can adequately replace virological criteria for 
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